<DOC>
	<DOCNO>NCT01690195</DOCNO>
	<brief_summary>This long term extension study evaluate safety tolerability subject complete study M11-793 evaluate new treatment subject mild moderate Alzheimer 's disease stable dose acetylcholinesterase inhibitor .</brief_summary>
	<brief_title>Safety Tolerability Study Evaluating New Treatment Subjects With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>This Phase 2 , open-label , multicenter , 28 week extension study evaluate long-term safety tolerability ABT-126 subject complete dose Week 24 Study M11-793 . Up 420 subject may participate approximately 40 site seven country .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>The subject caregiver must voluntarily sign date inform consent . If subject capacity provide inform consent , full informed consent must obtain subject 's representative assent must obtain subject . The subject randomize Study M11793 complete dose Week 24 study . With exception diagnosis mild moderate AD presence stable medical condition , subject general good health , base upon result medical history , physical examination , vital sign , laboratory profile , 12lead ECG . If male , subject surgically sterile ( vasectomy , sexually inactive , use barrier method birth control ( condom ) spermicidal foam/gel/film/cream/suppository duration study 30 day follow last dose study drug . However , male subject 's partner postmenopausal least two year surgically sterile , use barrier method birth control require . The subject identify , reliable caregiver provide support ensure compliance study medication procedure , provide accurate information subject 's status study . The subject caregiver must sufficient visual , hear graphomotor skill complete study procedure . The subject experience adverse event abnormal find physical examination , vital sign , laboratory profile and/or ECG measurement Study M11793 indicate subject could become medically unstable current study . The subject currently take expect prescribed exclude medication without approval Abbott medical monitor . The subject noncompliant donepezil rivastigmine Study M11793 expect discontinue medication prior conclusion study . The subject anticipate move outside geographic area investigative site planning extend travel inconsistent recommend visit interval . The subject currently enrol , plan participate , another experimental study course trial . The subject develop significant medical psychiatric condition , opinion investigator , render subject unsuitable candidate participate study . For reason investigator considers subject unsuitable candidate receive ABT126 participate study .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>